Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized trial of FLA+GO with or without venetoclax in children with relapsed AML
2021-003212-11Phase 3Active
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Dec 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of venetoclax, fludarabine, cytarabine and gemtuzumab ozogamicin in acute myeloid leukemia (AML) (2 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoint: overall survival. Started Dec 2021; status: active.
02
Drugs
venetoclaxfludarabinecytarabinegemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2021-003212-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003212-11.